The article is devoted to the concept of osteonecrosis formation in oncological patients with bone metastases taking bisphosphonate preparations. The significance of the problem of bisphosphonate osteonecrosis of the jaws is associated with an increase in the number of such patients over the past few decades, a high frequency of complications and relapses, and a negative prognosis of the disease. The number of inflammatory lesions of the jaws when using bisphosphonate preparations can reach 25% of the total number of patients, the number of abscesses and phlegmon reaches 45%. The article considers risk factors, the frequency of inflammatory lesions of the jaw bones, known approaches to the diagnosis and treatment of drug-associated osteonecrosis of the jaws.